We selected the luminal subtype instead of the HER2 subtype as a comparison group; this is because the HER2 subtype has a distinct tumor environment due to HER2-related pathways and an established treatment strategy (anti-HER2 agents). The gene discussed is ERBB2; the disease is neoplasm.